Related Experiment Videos
[Experimental study on carboplatin toxicity--a comparison with cisplatin]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 1, 1988
Summary
Carboplatin exhibits lower toxicity than cisplatin in rats, except for bone marrow. This difference is attributed to carboplatin's stable structure, leading to slower activation and reduced organ accumulation.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Cisplatin and carboplatin are platinum-based chemotherapy drugs.
- Understanding their comparative toxicities is crucial for clinical application.
Purpose of the Study:
- To compare the toxic potencies of cisplatin and carboplatin.
- To investigate the underlying mechanisms for observed toxicity differences.
Main Methods:
- Male Wistar rats were treated with cisplatin or carboplatin.
- Tissue platinum concentrations were measured.
- Histopathological examination of various organs was performed.
Main Results:
- Cisplatin treatment resulted in 5- to 13-fold higher tissue platinum concentrations compared to carboplatin.
- Carboplatin caused milder toxicity in kidneys, testes, spleen, and intestines, but severe myelosuppression.
- Cisplatin exhibited greater toxicity across all organs except bone marrow.
Conclusions:
- Carboplatin's reduced toxicity is linked to its stable dicarboxylate chelate ring, resulting in slower hydrolysis to the active form.
- Differences in nuclear protein phosphorylation and lower renal tubular accumulation contribute to carboplatin's decreased nephrotoxicity.